Tadamichi Denda

Head

Kanagawa Cancer Center

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Biology Cancer Biology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Tadamichi Denda is the Head at Chiba Cancer Center in Japan. His research focuses on metastatic colorectal cancer, particularly in the areas of clinical validation of plasma-based genotyping and the efficacy of combination therapies in advanced gastrointestinal cancers. Recent publications include studies on oxaliplatin therapy, tumor DNA analysis, and the role of RAS status in treatment outcomes.

Articles (6)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Taroh Satoh

Osaka University Hospital

JAPAN

View details

Hideo Baba

JAPAN

View details

Yoshito Komatsu

Hokkaido University Hospital

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tadamichi Denda

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)

Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy

Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program

Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer

Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

Collaborators (3)

Taroh Satoh

Hideo Baba

Yoshito Komatsu

Make your next move.